| 35.21 -0.5 (-1.4%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 45.03 | 1-year : | 48.92 |
| Resists | First : | 38.55 | Second : | 41.88 |
| Pivot price | 35.41  |
|||
| Supports | First : | 33.16 | Second : | 27.59 |
| MAs | MA(5) : | 34.87 |
MA(20) : | 36.28 |
| MA(100) : | 33.31 |
MA(250) : | 25.78 |
|
| MACD | MACD : | -1.2 |
Signal : | -1.2 |
| %K %D | K(14,3) : | 38.3 |
D(3) : | 28.5 |
| RSI | RSI(14): 44 |
|||
| 52-week | High : | 45.31 | Low : | 9.6 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ KYMR ] has closed above bottom band by 45.6%. Bollinger Bands are 32% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 36.3 - 36.49 | 36.49 - 36.66 |
| Low: | 34.23 - 34.44 | 34.44 - 34.62 |
| Close: | 34.86 - 35.22 | 35.22 - 35.53 |
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Tue, 23 Apr 2024
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $41.20 Consensus Target Price from Brokerages - MarketBeat
Mon, 22 Apr 2024
Kymera Therapeutics (NASDAQ:KYMR) Receives New Coverage from Analysts at Oppenheimer - MarketBeat
Wed, 17 Apr 2024
Kymera Therapeutics Enters Oversold Territory (KYMR) - Nasdaq
Thu, 21 Mar 2024
Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - Seeking Alpha
Sun, 03 Mar 2024
Analysts' Revenue Estimates For Kymera Therapeutics, Inc. (NASDAQ:KYMR) Are Surging Higher - Yahoo Finance
Tue, 27 Feb 2024
Piper Sandler Maintains Overweight Rating for Kymera Therapeutics: Here's What You Need To Know - Markets Insider
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 61 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 1.3 (%) |
| Held by Institutions | 102.8 (%) |
| Shares Short | 9,060 (K) |
| Shares Short P.Month | 8,250 (K) |
| EPS | -2.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.11 |
| Profit Margin | -187 % |
| Operating Margin | -40.4 % |
| Return on Assets (ttm) | -17.6 % |
| Return on Equity (ttm) | -33.3 % |
| Qtrly Rev. Growth | 196.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 1.28 |
| EBITDA (p.s.) | -2.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -103 (M) |
| Levered Free Cash Flow | -98 (M) |
| PE Ratio | -13.98 |
| PEG Ratio | -6.1 |
| Price to Book value | 4.95 |
| Price to Sales | 27.37 |
| Price to Cash Flow | -20.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|